Krazati (adagrasib)
- Medicine Name: Krazati
- Generic name: Adagrasib
- Dosage Forms and Strengths: It is available as Tablets: 200 mg
- Manufactured by: Mirati Therapeutics, Inc
Medical Uses
Indications and Usage:
Krazati is a breakthrough inhibitor of the RAS GTPase family designed to provide hope and effective treatment for adult patients battling KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This treatment is indicated for patients who have previously undergone at least one systemic therapy, as confirmed by an FDA-approved test. It’s important to note that this indication has been granted accelerated approval based on objective response rate (ORR) and duration of response (DOR). Further confirmation of clinical benefit may be required in confirmatory trials.
Dosage and Administration:
- Recommended Dosage: 600 mg orally twice daily.
- Tablets are to be swallowed whole, with or without food.
Contraindications:
- None
Warning & Precautions
- Gastrointestinal Adverse Reactions: Patients should be closely monitored for symptoms like diarrhea, nausea, and vomiting, with appropriate supportive care as needed. Dose adjustments may be required based on the severity of symptoms.
- QTc Interval Prolongation: Avoid concurrent use of Krazati with products known to prolong the QTc interval. Regularly monitor ECG and electrolytes in at-risk patients or those taking QT-prolonging medications. Adjust the dose or discontinue treatment as necessary.
- Hepatotoxicity: Before starting Krazati and monthly for three months after, as well as when clinically indicated, conduct liver laboratory tests. Dose adjustments, temporary suspension, or permanent discontinuation may be necessary depending on the severity of hepatotoxicity.
- Interstitial Lung Disease / Pneumonitis: Monitor for the development of new or worsening respiratory symptoms. If suspected, temporarily withhold Krazati and discontinue if no alternative causes of ILD/pneumonitis are identified.
Adverse Reactions:
- The most common adverse reactions (≥ 25%) include nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, and decreased appetite.
- Common Grade 3 or 4 laboratory abnormalities (≥ 2%) consist of decreased lymphocytes, decreased hemoglobin, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, increased lipase, decreased leukocytes, decreased neutrophils, and increased alkaline phosphatase.
Drug Interactions:
For detailed information on clinically significant drug interactions with Krazati , please refer to the full prescribing information. Key points to note include avoiding concomitant use with strong CYP3A4 inducers or inhibitors, sensitive CYP3A4 substrates, sensitive CYP2C9 or CYP2D6 substrates, P-gp substrates, and drugs that prolong the QT interval. These precautions help ensure the safety and effectiveness of the treatment.
Documentation & Availability
What documents are required to import Krazati to India?
Krazati (adagrasib) tablets can be imported by patients or government hospitals on behalf of patients. The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is Krazati available in India?
Krazati (adagrasib) tablets are a prescription pharmaceutical drug that legally requires a medical prescription for dispensation.
S S Healthcare facilitates the import of critical medications like Krazati into India, ensuring the named patient supply (NPS). S S Healthcare is the facilitator that provides essential support for:
- Availability of Krazati in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, and more).
- Determining Medicine Price.
- Sourcing genuine and reliable sources from the USA, Canada, Europe, and Australia.
- Ensuring 100% transparency.
Krazati can be made available to patients, doctors, and hospitals in various cities across India. The order will be confirmed only after receiving a valid prescription from the doctor and, if required, an import permit.
S S Healthcare can facilitate the supply of Krazati (prescription medicine) to locations worldwide and in India while adhering to legal requirements (if applicable).
Sourcing & Delivery
S S Healthcare is proficient in sourcing Krazati from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.
S S Healthcare is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities
FAQ
What is Krazati used for?
Krazati treats KRAS G12C-mutated non-small cell lung cancer (NSCLC) in adults who’ve had prior systemic therapy.
How does Krazati work?
Krazati inhibits the KRAS G12C mutation, impeding cancer cell growth.
Who is eligible for Krazati?
Adults with KRAS G12C-mutated NSCLC confirmed by an FDA-approved test and who’ve had prior therapy.
What are common side effects?
Common side effects include nausea, diarrhea, fatigue, and more. Discuss with your healthcare provider.
Is Krazati available in India?
Yes, it’s available with a valid doctor’s prescription and required documentation.
Is Krazati FDA approved?
Krazati got approved by the FDA in 2022.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
